EX-99.1 7 ex99-1.htm ex99-1.htm
Exhibit 99.1
 
Umicron Ltd.

(A Development Stage Company)

August 31, 2013

Index to the Financial Statements


Contents
 
Page(s)
     
Report of Independent Registered Public Accounting Firm
 
F-2
     
Balance Sheet at August 31, 2013
 
F-3
     
Statement of Operations for the Period from December 6, 2012 (Inception) to August 31, 2013
 
F-4
     
Statement of Stockholders’ Equity (Deficit) for the Period from December 6, 2012 (Inception) to August 31, 2013
 
F-5
     
Statement of Cash Flows for the Period from December 6, 2012 (Inception) to August 31, 2013
 
F-6
     
Notes to the Financial Statements
 
F-7

 
 
F-1

 
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors of
Umicron, Ltd.
(a development stage company)
Suffolk, United Kingdom

We have audited the accompanying balance sheets of Umicron Ltd. (a development stage company) (the “Company”) as of August 31, 2013, and the related statements of operations, changes in stockholders’ equity, and cash flows for the period from December 6, 2013 (inception) through August 31, 2013. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Umicron, Ltd. as of August 31, 2013, and the results of its operations and its cash flows for the period from December 6, 2013 (inception) through August 31, 2013 in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that Umicron, Ltd. will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has suffered losses from operations and negative cash flows which raise substantial doubt about its ability to continue as a going concern. Management’s plans regarding those matters also are described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 
/s/ MaloneBailey, LLP            
www.malonebailey.com
Houston, Texas

October 18, 2013
 
 
F-2

 

Umicron Ltd.
(A Development Stage Company)
Balance Sheet


   
August 31, 2013
 
Assets
     
       
Current assets
     
Cash
  $ 6,782  
Deposit
    1,880  
         
    Total current assets
    8,662  
         
Non-current assets
       
Machinery
    11,005  
         
    Total assets
  $ 19,667  
         
Liabilities and stockholders' equity
       
         
Current liability
       
Accrued expenses
  $ 1,250  
         
    Total current liabilities
    1,250  
         
 Stockholders' equity
       
Common stock: £1 par value ($1.55 as of August 31, 2013),
       
1,000 shares authorized;1,000 shares issued and outstanding
    1,514  
Additional Paid in Capital
    148,971  
Deficit accumulated during the development stage
    (132,068 )
         
    Total stockholders' equity
    18,417  
         
    Total liabilities and stockholders' equity
  $ 19,667  




See accompanying notes to the financial statements.

 
F-3

 

Umicron Ltd.
(A Development Stage Company)
Statement of Operations


   
For the Period from
 
   
December 6, 2012
 
   
(inception) through
 
   
August 31, 2013
 
       
Revenues
  $ -  
         
Operating expenses
       
Rent
    12,137  
Office and miscellaneous
    4,599  
Research and development
    3,696  
Amortization
    1,202  
Professional fees
    2,108  
Consulting
    108,326  
         
    Total operating expenses
    132,068  
         
Net loss
  $ (132,068 )
         
Net loss per common share: - Basic and diluted
  $ (188.67 )
         
Weighted average common shares outstanding - basic and diluted
    700  




See accompanying notes to the financial statements.

 
F-4

 

Umicron Ltd.
(A Development Stage Company)
Statement of Stockholders' Equity (Deficit)
For the Period from December 6, 2012 (Inception) through August 31, 2013


   
 
   
 
   
Deficit
   
 
 
               
 
   
Accumulated
   
Total
 
   
 
   
 
   
Additional
   
during the
   
Stockholders'
 
   
Common Stock, Par Value $0.1826
   
paid-in
   
Development
   
Equity
 
   
Number of Shares
   
Amount
   
Capital
    Stage     (Deficit)  
                               
 Balance, December 6, 2012 (inception)
    -     $ -     $ -     $ -     $ -  
                                         
 Shares issued to founder
    900       1,363       (1,363 )             -  
 Shares issued for consulting services
    60       91       45,548       -       45,639  
 Shares issued for cash
    40       60       29,786       -       29,846  
 Contributed Services
                    75,000               75,000  
 Net loss
                            (132,068 )     (132,068 )
                                         
 Balance, August 31, 2013
    1,000     $ 1,514     $ 148,971     $ (132,068 )   $ 18,417  




See accompanying notes to the financial statements.

 
F-5

 

Umicron Ltd.
(A Development Stage Company)
Statement of Cash Flows


   
For the Period from
 
   
December 6, 2012
 
   
(inception) through
 
   
August 31, 2013
 
Cash flows from operating activities:
     
Net loss
  $ (132,068 )
Non cash items
       
Depreciation
    1,202  
Stock based compensation
    45,639  
Contributed Services
    75,000  
Changes in operating assets and liabilities:
       
Deposit
    (1,880 )
Accrued liabilities
    1,250  
         
Net cash used in operating activities
    (10,857 )
         
Cash flows from investing activities
       
Purchase of equipment
    (12,207 )
         
Cash flows from financing activity
       
Proceeds from sale of common stock
    29,846  
         
         
Net change in cash
    6,782  
         
Cash, beginning of period
    -  
         
Cash, end of period
  $ 6,782  
         
Supplemental disclosure of cash flows information:
       
Interest paid
  $ -  
Income tax paid
  $ -  




See accompanying notes to the financial statements.

 
F-6

 

Umicron Ltd.
(A Development Stage Company)
August 31, 2013
Notes to the Financial Statements


Note 1 – Organization and Operations

Umicron Ltd.

Umicron Ltd. (“Umicron”), a development stage company, was incorporated on December 6, 2012 under the laws of England and Wales to engage in any lawful business or activity for which corporations may be organized under the laws of England and Wales.  Umicron intends to engage in the development and sale of 3D printers.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation

The Company’s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Development Stage Company
 
The Company is a development stage company as defined by section 915-10-20 of the FASB Accounting Standards Codification. The Company is still devoting substantially all of its efforts on establishing the business and its planned principal operations have not commenced.  All losses accumulated since inception have been considered as part of the Company's development stage activities.

Use of Estimates and Assumptions

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reporting amounts of revenues and expenses during the reporting period.

The Company’s significant estimates and assumptions include the fair value of financial instruments; income tax rate, income tax provision, deferred tax assets and valuation allowance of deferred tax assets; the carrying value and recoverability of long-lived assets, including the values assigned to an estimated useful lives of website development costs and the assumption that the Company will be a going concern. Those significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to those estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.

Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.

 
F-7

 

Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly.

Actual results could differ from those estimates.
 
Foreign currency translation

Assets and liabilities of foreign operations are translated into United States dollar equivalents using the exchange rates in effect at the balance sheet date. Revenues and expenses are translated using the average exchange rates during each period. Adjustments resulting from the process of translating foreign functional currency financial statements into U.S. dollars are included in accumulated other comprehensive income in common shareholders’ equity. Foreign currency transaction gains and losses are included in current earnings were nominal for the initial period presented..
 
Fiscal Year-End

The Company elected August 31 as its fiscal year ending date.

Cash Equivalents

The Company considers all highly liquid investments with maturities of three months or less at the time of purchase to be cash equivalents.

Related Parties

The Company follows subtopic 850-10 of the FASB Accounting Standards Codification for the identification of related parties and disclosure of related party transactions.

Pursuant to section 850-10-20 the related parties include a) affiliates of the Company; b) entities for which investments in their equity securities would be required, absent the election of the fair value option under the Fair Value Option Subsection of section 825–10–15, to be accounted for by the equity method by the investing entity; c) trusts for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of management; d) principal owners of the Company; e) management of the Company; f) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and g.  other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

The financial statements shall include disclosures of material related party transactions, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include:  a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which income statements are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which income statements are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d. amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

 
 
F-8

 
 
Commitments and Contingencies

The Company follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditions may exist as of the date the consolidated financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur.  The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment.  In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
 
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s consolidated financial statements.  If the assessment indicates that a potentially material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.

Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.  Management does not believe, based upon information available at this time, that these matters will have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. However, there is no assurance that such matters will not materially and adversely affect the Company’s business, financial position, and results of operations or cash flows.

Revenue Recognition

The Company applies paragraph 605-10-S99-1 of the FASB Accounting Standards Codification for revenue recognition.  The Company recognizes revenue when it is realized or realizable and earned.  The Company considers revenue realized or realizable and earned when all of the following criteria are met: (i) persuasive evidence of an arrangement exists, (ii) the product has been shipped or the services have been rendered to the customer, (iii) the sales price is fixed or determinable, and (iv) collectability is reasonably assured.
 
Research and development

Costs incurred in connection with the development of new products and manufacturing methods are charged to selling, general and administrative expenses as incurred.
 
Income Tax Provision

The Company adopted the provisions of paragraph 740-10-25-13 of the FASB Accounting Standards Codification. Paragraph 740-10-25-13.addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements.  Under paragraph 740-10-25-13, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position.  The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement.  Paragraph 740-10-25-13 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures.  The Company had no material adjustments to its liabilities for unrecognized income tax benefits according to the provisions of paragraph 740-10-25-13.

The estimated future tax effects of temporary differences between the tax basis of assets and liabilities are reported in the accompanying consolidated balance sheets, as well as tax credit carry-backs and carry-forwards. The Company periodically reviews the recoverability of deferred tax assets recorded on its consolidated balance sheets and provides valuation allowances as management deems necessary.

Management makes judgments as to the interpretation of the tax laws that might be challenged upon an audit and cause changes to previous estimates of tax liability. In addition, the Company operates within multiple taxing jurisdictions and is subject to audit in these jurisdictions. In management’s opinion, adequate provisions for income taxes have been made for all years. If actual taxable income by tax jurisdiction varies from estimates, additional allowances or reversals of reserves may be necessary.

 
F-9

 

Uncertain Tax Positions

The Company did not take any uncertain tax positions and had no adjustments to unrecognized income tax liabilities or benefits pursuant to the provisions of Section 740-10-25 for the period from December 6, 2012 (inception) through August 31, 2013.

Net Income (Loss) per Common Share

Net income (loss) per common share is computed pursuant to section 260-10-45 of the FASB Accounting Standards Codification.   Basic net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period.  Diluted net income (loss) per common share is computed by dividing net income (loss) by the weighted average number of shares of common stock and potentially outstanding shares of common stock during the period to reflect the potential dilution that could occur from common shares issuable through contingent shares issuance arrangement, stock options or warrants.

There were no potentially outstanding dilutive shares for the period from December 6, 2012, 2012 (inception) through August 31, 2013.

Recently Issued Accounting Pronouncements

Management does not believe that any recently issued accounting pronouncements would have a material effect on the accompanying consolidated financial statements.

Note 3 – Going Concern

The financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and liquidation of liabilities in the normal course of business. 

As reflected in the financial statements, the Company had a deficit accumulated during the development stage at August 31, 2013, a net loss and net cash used in operating activities for the period from December 6, 2012 (inception) through August 31, 2013. These factors raise substantial doubt about the Company’s ability to continue as a going concern.
 
While the Company is attempting to commence operations and generate revenues, the Company’s cash position may not be significant enough to support the Company’s daily operations. Management intends to raise additional funds by way of a public or private offering.  Management believes that the actions presently being taken to further implement its business plan and generate revenues provide the opportunity for the Company to continue as a going concern. While the Company believes in the viability of its strategy to increase revenues and in its ability to raise additional funds, there can be no assurances to that effect. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to further implement its business plan and generate revenues.

The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
 
 
F-10

 

Note 4 – Equipment

Equipment is stated at cost less accumulated depreciation.  Depreciation is computed using the straight-line method over the estimated useful lives of the assets which is 5 years.

Description
 
Cost
   
Accumulated
Amortization
   
Net Book
Value
 
                   
Equipment
  $ 12,207     $ 1,202     $ 11,005  

Note 5 – Lease commitments
 
The Company leases an industrial premises for $9,625 per year through March 31, 2016.  The Company has the option to cancel the lease with three months notice starting January 1, 2014.  The Company leases a live/work premises for $2,079 per month until April 30, 2014.  A table of minimum lease payments due is as follows:

Year ended August 31, 2014       $19,840
 
Note 6 – Stockholders’ Equity

Shares Authorized

Upon formation the total number of shares of common stock which the Company is authorized to issue is unlimited.
 
Common Stock
 
On December 6, 2012, the Company issued 900 shares to its founder at zero valuation.
  
On March 11, 2013, the Company issued 40 shares to two third parties for services with a total value of $29,846

During the period the Company sold 60 shares for total proceeds of $45,639.
 
During the period, various stockholders performed services for the Company valued at $75,000.
 
Note 6 – Income Tax Provision

Deferred tax assets
 
At August 31, 2013, the Company had net operating loss (“NOL”) carry–forwards for English income tax purposes of $11,429 that may be offset against future taxable income, expiring in 2033.  No tax benefit has been reported with respect to these net operating loss carry-forwards in the accompanying financial statements because the Company believes that the realization of the Company’s net deferred tax assets of approximately $2,700 was not considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are fully offset by a full valuation allowance.  Components of deferred tax assets are as follows:

   
August 31, 2013
 
Net deferred tax assets – Non-current:
       
Expected income tax benefit from NOL carry-forwards
 
$
2,700
 
Less: Valuation allowance
   
(2,700
)
       
    Deferred tax assets, net of valuation allowance
 
$
-
 
 

 
F-11